Summit Therapeutics Inc. (SMMT) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 13.70B USD. 52-week range 12.07 to 29.23 USD. Data as of 2026-10-09.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical ...